HDAC9 and lymphoma: Older classes of epigenetic therapies, such as pan-HDAC inhibitors, are associated with high rates of toxicity and poor target selectivity, but newer classes, such as EZH2 inhibitors, have higher selectivity and better safety profiles and are being tested in a variety of lymphomas.